Related Experiment Videos
Connatal Pelizaeus-Merzbacher disease
C A Haenggeli1, E Engel, G P Pizzolato
1Department of Paediatrics, Hôpital Cantonal Universitaire, Geneva, Switzerland.
Developmental Medicine and Child Neurology
|December 1, 1989
Summary
Pelizaeus-Merzbacher disease type II is a rare nervous system disorder. Unique clinical features in an infant may enable early presumptive diagnosis and genetic counseling before autopsy confirmation.
Area of Science:
- Neurology
- Genetics
- Developmental Biology
Background:
- Pelizaeus-Merzbacher disease (PMD) is a rare, X-linked recessive congenital disorder.
- It is characterized by progressive demyelination in the central nervous system.
- Currently, definitive diagnosis relies on histopathological examination post-mortem.
Observation:
- The study presents a case of Type II connatal Pelizaeus-Merzbacher disease.
- The infant exhibited a constellation of clinical signs and symptoms.
- These features appear to be distinct and potentially unique to this specific subtype of PMD.
Findings:
- The identified clinical features may serve as early indicators for Type II PMD.
- This could facilitate a presumptive clinical diagnosis in affected infants.
- Histopathological confirmation remains the gold standard but is post-mortem.
Implications:
- Early presumptive diagnosis can significantly impact patient management.
- It allows for timely and crucial genetic counseling for families.
- This approach offers the potential to provide support before the infant's prognosis is confirmed by autopsy.